Latest News

Senhwa Biosciences Receives US FDA ‘Study May Proceed’ Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461

Dec

24

2020

Senhwa Biosciences’s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium

Dec

14

2020

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial of Silmitasertib as a Treatment for COVID-19

Dec

03

2020

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Nov

25

2020

Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19

Nov

02

2020

Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment

Sep

11

2020

Senhwa Biosciences’s Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma

Jul

06

2020

Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19

Jul

02

2020